从胃肠外前列环素过渡到司来帕格：特定患者中的安全性和可行性
Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients.
作者信息
Aldweib Nael, Verlinden Nathan J, Kassis-George Hayah, Raina Amresh
机构信息
Section of Advanced Heart Failure and Pulmonary Hypertension, Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Allegheny General Hospital, Pittsburgh, USA.
Adult Congenital Heart Disease Program, Knight Cardiovascular Institute, Oregon Health Science University, Portland, USA.
出版信息
Pulm Circ. 2021 Oct 9;11(4):20458940211036623. doi: 10.1177/20458940211036623. eCollection 2021 Oct-Dec.
Abstract
There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
摘要
关于肺动脉高压患者从静脉注射前列环素转换为司来帕格的可行性数据有限。我们报告了一系列病例，在门诊环境中，通过标准化方案，大多数精心挑选的五名稳定的肺动脉高压患者成功地从静脉注射前列环素转换为司来帕格。
相似文献
1
Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients.从胃肠外前列环素过渡到司来帕格：特定患者中的安全性和可行性
Pulm Circ. 2021 Oct 9;11(4):20458940211036623. doi: 10.1177/20458940211036623. eCollection 2021 Oct-Dec.
2
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.从肠外前列腺素到塞来昔帕用于肺动脉高压的转换经验。
J Cardiovasc Pharmacol. 2020 Apr;75(4):299-304. doi: 10.1097/FJC.0000000000000800.
3
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension.小儿肺动脉高压患者从肠外前列环素转换为司来帕格的血流动力学评估。
Pulm Circ. 2022 Oct 1;12(4):e12159. doi: 10.1002/pul2.12159. eCollection 2022 Oct.
4
Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.将肺动脉高压稳定患者从肠外前列腺素过渡到口服司来帕格
Biomed Hub. 2022 Oct 7;7(3):115-124. doi: 10.1159/000526190. eCollection 2022 Sep-Dec.
5
Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.司来帕格在先天性心脏病相关肺动脉高压中的当代应用：病例系列
Eur Heart J Case Rep. 2020 Nov 7;4(6):1-7. doi: 10.1093/ehjcr/ytaa320. eCollection 2020 Dec.
6
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.肺动脉高压患者从曲前列尼尔转换为司来帕格治疗：病例系列
Am J Health Syst Pharm. 2018 Dec 1;75(23):1877-1881. doi: 10.2146/ajhp170814. Epub 2018 Oct 9.
7
Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.肺动脉高压中前列环素类药物治疗的转换
Front Med (Lausanne). 2020 Mar 31;7:81. doi: 10.3389/fmed.2020.00081. eCollection 2020.
8
Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.三名青少年肺动脉高压患者从静脉注射曲前列尼尔快速转换为口服司来帕格的安全性和耐受性
J Pediatr Pharmacol Ther. 2021;26(5):512-516. doi: 10.5863/1551-6776-26.5.512. Epub 2021 Jun 28.
9
Prostacyclin for pulmonary arterial hypertension.前列环素用于肺动脉高压
Cochrane Database Syst Rev. 2019 May 1;5(5):CD012785. doi: 10.1002/14651858.CD012785.pub2.
10
Direct prostacyclin transition in pediatric patients with pulmonary hypertension.小儿肺动脉高压患者的直接前列环素转换
Pulm Circ. 2024 May 5;14(2):e12373. doi: 10.1002/pul2.12373. eCollection 2024 Apr.
引用本文的文献
1
Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.特发性肺动脉高压患者静脉用依前列醇转换为口服塞立帕格：1 例报告。
ESC Heart Fail. 2023 Aug;10(4):2722-2727. doi: 10.1002/ehf2.14428. Epub 2023 Jun 19.
2
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension.小儿肺动脉高压患者从肠外前列环素转换为司来帕格的血流动力学评估。
Pulm Circ. 2022 Oct 1;12(4):e12159. doi: 10.1002/pul2.12159. eCollection 2022 Oct.
3
Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag.将肺动脉高压稳定患者从肠外前列腺素过渡到口服司来帕格
Biomed Hub. 2022 Oct 7;7(3):115-124. doi: 10.1159/000526190. eCollection 2022 Sep-Dec.
4
Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.基于司来帕格的三联联合疗法可改善中国肺动脉高压患者的预后。
Front Cardiovasc Med. 2022 Sep 20;9:991586. doi: 10.3389/fcvm.2022.991586. eCollection 2022.
本文引用的文献
1
Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.肺动脉高压患者从静脉注射依前列醇转换为司来帕格治疗：需谨慎行事。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.02418-2019. Print 2020 Jun.
2
Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.从肠外前列腺素到塞来昔帕用于肺动脉高压的转换经验。
J Cardiovasc Pharmacol. 2020 Apr;75(4):299-304. doi: 10.1097/FJC.0000000000000800.
3
Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor.使用植入式血流动力学传感器监测肺动脉高压。
Chest. 2019 Dec;156(6):1176-1186. doi: 10.1016/j.chest.2019.06.010. Epub 2019 Jun 29.
4
EXPRESS: Transition from Parental Prostacyclin to Selexipag: A Case Series of Five Pulmonary Arterial Hypertension Patients.快报：从父母的前列环素过渡到司来帕格：五例肺动脉高压患者的病例系列
Pulm Circ. 2019 Jun 19;9(3):2045894019862167. doi: 10.1177/2045894019862167.
5
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.预测肺动脉高压患者的生存情况：REVEAL 风险评分计算器 2.0 与 ESC/ERS 风险评估策略的比较。
Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
6
Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.在肺动脉高压治疗转换期间使用植入式无线肺动脉压力监测仪。
J Heart Lung Transplant. 2019 Feb;38(2):227-230. doi: 10.1016/j.healun.2018.11.011. Epub 2018 Nov 24.
7
Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.成人肺动脉高压治疗：CHEST 指南和专家小组报告更新。
Chest. 2019 Mar;155(3):565-586. doi: 10.1016/j.chest.2018.11.030. Epub 2019 Jan 17.
8
Selexipag for the Treatment of Pulmonary Arterial Hypertension.塞乐西帕用于肺动脉高压的治疗。
N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184.
9
Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.肺动脉高压患者从静脉注射前列环素转为口服波生坦的结果。
Respir Med. 2009 Nov;103(11):1688-92. doi: 10.1016/j.rmed.2009.05.009. Epub 2009 Jun 17.
Zotero 插件